5-Amino-1MQ gets sold alongside peptides and talked about the same way, but it isn’t one — it’s a small molecule designed to inhibit an enzyme called NNMT (nicotinamide N-methyltransferase), which is involved in regulating cellular energy metabolism and has drawn interest for a possible role in fat cell regulation.

What NNMT Actually Does

NNMT methylates nicotinamide, consuming a methyl donor and influencing the cellular NAD+ pool in the process. Preclinical work has linked elevated NNMT activity in fat tissue to metabolic changes, which is the basis for interest in inhibiting it.

“People shop for it next to peptides and treat it like one. It isn’t, and that changes what you should actually be asking about it.”

— a metabolic biochemist who reviewed the preclinical literature for this piece

The Preclinical-to-Product Gap

Almost all of the specific-compound data on 5-Amino-1MQ is preclinical — cell culture and rodent studies. Human trial data on this specific molecule at consumer-relevant doses is not publicly available in the way it is for compounds with a clinical development history.

Why the “Not a Peptide” Distinction Matters

Buyers researching “peptides” by habit may apply assumptions — about dosing conventions, injection practice, degradation behavior — that come from peptide chemistry and don’t necessarily transfer to a small molecule with a different structure and pharmacokinetic profile.